Forest Laboratories, Inc. Reports Fiscal Year 2009 Fourth Quarter Reported EPS of $0.31 Including $0.45 Per Share Charge Related to the Ongoing United States Attorney's Office Inv... (performance. Accordingly we expect to e...)

HOME >> MEDICINE >> NEWS

Forest Laboratories, Inc. Reports Fiscal Year 2009 Fourth Quarter Reported EPS of $0.31 Including $0.45 Per Share Charge Related to the Ongoing United States Attorney's Office Investigation

Date:4/21/2009

performance. Accordingly, we expect to enter into additional development agreements for product opportunities during this and subsequent years. We believe that supporting our currently marketed products and seeking additional compounds through our business development efforts will deliver the sales and earnings necessary to both replace and exceed the revenues lost due to the expiry of marketing exclusivity for Lexapro and Namenda."

Use of Non-GAAP Financial Information

This press release contains non-GAAP earnings per share information adjusted to exclude certain costs, expenses and other specified items as summarized in the table below. This information is intended to enhance an investor's overall understanding of the Company's past financial performance and prospects for the future. This information is not intended to be considered in isolation or as a substitute for diluted earnings per share prepared in accordance with GAAP.

FOREST LABORATORIES, INC. AND SUBSIDIARIES
SUPPLEMENTAL FINANCIAL INFORMATION

THREE MONTHS TWELVE MONTHS
ENDED MARCH 31 ENDED MARCH 31
2008 2009 2008 2009
Reported Diluted Earnings
Per Share: $0.55 $0.31 $3.06 $2.52
Specified items, per share,
net of tax:
USAO Investigation - 0.45 - 0.45
Azor Deal Termination - - - 0.08
Research and Development
Ironwood Licensing Payment - 0.15 -
Novexel Licensing Payment 0.35 - 0.35 -
Phenomix and Pierre Fabre
Licensing Payments - - - 0.41

Adjusted Non-GAAP Diluted

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11
Related medicine news :

1. AUDIO from Medialink and Forest Pharmaceuticals: FDA Approves Lexapro for Major Depressive Disorder in Adolescents
2. Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Commercial Availability of Savella(TM)
3. AUDIO from Medialink and Forest Pharmaceuticals: FDA Approves Lexapro for Major Depressive Disorder in Adolescents
4. Forest Laboratories, Inc. Announces FDA Approval of Lexapro(R) for the Treatment of Major Depressive Disorder in Adolescents
5. German Federal Patent Court Invalidates Wake Forest NPWT Patents Licensed to KCI
6. Wake Forest Baptist and Rivulet Connect New Operating Rooms with Interactive Video
7. Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Revised Timing for Commercial Availability of Savella(TM)
8. Forest Laboratories, Inc. Provides Statement in Response to Complaint Filed by U.S. Government
9. United States Files Complaint Against Forest Laboratories for Allegedly Violating the False Claims Act
10. Old-Growth Forests Dying Off in U.S. West
11. Forest Laboratories, Inc. Reports Q309 Diluted Earnings Per Share of $0.62, Including $0.41 Per Share Charge for New Product Licensing Fees

Post Your Comments:

Forest Laboratories, Inc. Reports Fiscal Year 2009 Fourth Quarter Reported EPS of $0.31 Including $0.45 Per Share Charge Related to the Ongoing United States Attorney's Office Inv...(performance. Accordingly we expect to e...),Health